Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Yoshiyuki Furuse"'
Autor:
Masahiko Kato, Yoshiyuki Furuse, Tomomi Watanabe, Kazuhiro Yamamoto, Kinya Shirota, Naoko Sasaki, Natsuko Mukai-Yatagai, Toshihiko Akasaka
Publikováno v:
International Heart Journal. 61:295-300
Many patients are transferred to hospital due to out-of-hospital cardiac arrest (OHCA), and, unfortunately, most suffer from cerebral damage. Currently, it is difficult to predict the recovery of neurological function after return of spontaneous circ
Autor:
Tomomi Watanabe, Natsuko Mukai-Yatagai, Toshihiko Akasaka, Naoko Sasaki, Kazuhiro Yamamoto, Yoshiyuki Furuse
Publikováno v:
Journal of cardiovascular medicine (Hagerstown, Md.). 22(2)
Autor:
Tomomi Watanabe, Yoshiyuki Furuse, Kazuhiro Yamamoto, Masahiko Kato, Yasutoshi Ohta, Toshihide Ogawa
Publikováno v:
International Heart Journal. 57:558-564
Non-ST segment elevation acute coronary syndrome (NSTE-ACS) can be difficult to diagnose accurately, especially in the hyper-acute phase. Non-ECG-gated contrast-enhanced computed tomography (non-ECG-gated CE-CT) has been used in many institutions for
Autor:
Yoshiyuki, Furuse, Kazuhiro, Yamamoto
Publikováno v:
Nihon rinsho. Japanese journal of clinical medicine. 74
Autor:
Yasutoshi Ohta, Kazuhiro Yamamoto, Toshihide Ogawa, Shinichiro Kitao, Hiroto Yunaga, Yoshiyuki Furuse, Tomomi Watanabe, Yasuhiro Kaetsu
Publikováno v:
European radiology. 27(7)
Multi-detector-row computed tomography angiography (MDCTA) plays an important role in the assessment of patients with suspected coronary artery disease. However, MDCTA tends to overestimate stenosis in calcified coronary artery lesions. The aim of ou
Autor:
Chiaki Shigemasa, Ichiro Hisatome, Tetsuya Yamamoto, Tetsuya Shiomi, Kazuhide Ogino, Yoshiharu Kinugasa, Yoshiyuki Furuse, Osamu Igawa, Hiroyuki Tsutsui
Publikováno v:
Circulation Journal. 67:781-787
It has been reported that the xanthine oxidase inhibitor, allopurinol, has a protective effect on ischemia - reperfusion injury, but the precise mechanism of its action is still unclear. Therefore, in the present study the mechanisms of the myocardia
Autor:
Kazuhide Ogino, Osamu Igawa, Yoko Tomikura, John P. Bilezikian, Yoshiyuki Furuse, Masahiko Kato, Toru Kinugawa, Shuichi Osaki, Kazuyoshi Ogura, Kazuhiko Uchida, Yoshiharu Kinugasa, Chiaki Shigemasa, Ichiro Hisatome, Masaki Shimoyama
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 87:4722-4727
PTHrP is produced in a wide variety of different cells, including cardiomyocytes. Its production is augmented by mechanical and neurohumoral stimulation, and PTHrP has positive chronotropic and vasodilatory effects. Thus, in the heart, PTHrP has the
Autor:
Masaru Kato, Tomohisa Okamura, Kazuhiko Sonoyama, Yasunori Tanaka, Junichiro Miake, Hiroaki Tanaka, Naomasa Makita, Ichiro Hisatome, Yasutaka Kurata, Kazuhide Ogino, Masaki Shimoyama, Osamu Igawa, Akio Yoshida, Yoshiyuki Furuse, Norihito Sasaki, Yasutaka Yamamoto, Kazuhiko Ogura, Gias U. Ahmmed, Chiak Shigemasa
Publikováno v:
Vascular Pharmacology. 38:131-141
The effects of moricizine on Na+ channel currents (INa) were investigated in guinea-pig atrial myocytes and its effects on INa in ventricular myocytes and on cloned hH1 current were compared using the whole-cell, patch-clamp technique. Moricizine ind
Autor:
Shuichi Osaki, Kazuhide Ogino, Yoshiyuki Furuse, T Kinugawa, Osamu Igawa, C. Shigemasa, Masahiko Kato, Hisatome, Yoko Tomikura
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 40:69-74
Objective: This study determined whether alacepril treatment improves exercise hemodynamics in patients with heart failure. Methods: Supine bicycle ergometer exercise was performed after administration of placebo and after acute and chronic (12 weeks
Autor:
Shiro Ikawa, Kazuhiko Uchida, Masahiko Kato, Osamu Igawa, Yoshiyuki Furuse, Toru Kinugawa, Masaki Shimoyama, Chiaki Shigemasa, Shuichi Osaki, Kazuhide Ogino, Ichiro Hisatome, Akihiro Endo
Publikováno v:
Cardiovascular Drugs and Therapy. 16:215-220
Troglitazone increased cardiac output and stroke volume, as a result of decreased peripheral resistance, in diabetic patients with normal cardiac function. The cardiovascular effects of troglitazone in patients with heart failure are unknown. The aim